The 2019 STAT Summit: ‘You Don’t Burn the House Down to Get Rid of Rats’

Posted by Ed Schoonveld on Tue, Nov 26, 2019

Many senior leaders in the healthcare and pharmaceutical space gathered at the inaugural STAT Summit on Nov. 21st at the MIT campus in Cambridge, Mass. The invitation-only summit featured an interesting mix of exciting medical scientific advances, including bionic limbs, artificial intelligence, the impact of real-world evidence on drug development, and patient testimonials regarding some great medical and pharmaceutical innovations.


>
Read More

Global Fair Pricing Tensions

Posted by Ed Schoonveld on Thu, May 16, 2019

Pricing for prescription drugs has been a contentious issue around the world as payers and patients don’t understand the cause of high drug prices and are struggling with patient access. Particularly in middle- and low-income countries, affordability of drugs in cancer has become an important part of a dialogue between the World Health Organization, governments, non-governmental organizations and patient advocates. The WHO has organized several meetings to explore and drive resolutions for drug-pricing-related issues for patented and generic drugs.


>
Read More

Dangerous, Simple Drug Pricing Solutions

Posted by Ed Schoonveld on Thu, Mar 21, 2019

At a time when drug company CEOs are questioned in Congress and polarized U.S. Democrats and Republicans appear to unite in an intent to act on drug pricing, the industry needs to be very concerned. U.S. politicians and academics are exploring ways to satisfy public thirst for lower drug cost. The biggest danger in today’s Twitter world is the appeal of seemingly simple solutions such as a single-payer system, international price index, ICER and, recently, a three-part pricing model.


>
Read More

Designing a Value Strategy

Posted by Ed Schoonveld on Thu, Mar 07, 2019

How do we use the access journey framework to design a winning value strategy in the age of value and affordability?


>
Read More

The Access Journey

Posted by Ed Schoonveld on Thu, Feb 21, 2019

How do we devise an optimal strategy to ensure patient access to our treatments in an age of value and affordability? How do we incorporate the impact of payers, medical communities, providers, prescribers and patients in a framework that helps us make trade-offs for development and commercialization decisions? It’s time to start the “access journey.”


>
Read More